Crystal Adam sold $618K of TNGX

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

Tango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat, showing strong efficacy in pancreatic and lung cancers when combined with Revolution Medicines' (RVMD) RAS(ON) inhibitors. The combination achieved 82% and 80% response rates in pancreatic and lung cancer patients, respectively. Tango plans a global registrational study in 2027. TNGX shares fell 10.65% to $24.95 on Friday.

Tango Therapeutics (TNGX) shares dropped 13% after reporting an 82% response rate for its drug combination in pancreatic cancer patients, slightly lower than June's 92%. The Phase 3 trial is not expected to start until 2027. The company had $1.0 billion in cash at the end of June and is awaiting FDA discussions on a faster approval path.

Tango Therapeutics (TNGX) shares fell 16% despite presenting pancreatic cancer trial data showing an 82% response rate. The stock had risen 28% before the release. The trial tested vopimetostat with Revolution Medicines' daraxonrasib. Phase 3 plans are set for 2027. Investors may have taken profits after the stock's recent gains.

Tango Therapeutics (TNGX) reported 82% response rate for vopimetostat + daraxonrasib in pancreatic cancer. Plans Phase 3 trial in 2027. Stock down 8.88% in pre-market.